TLR5 agonist in combination with anti-PD-1 treatment enhances anti-tumor effect through M1/M2 macrophage polarization shift and CD8+ T cell priming
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03679-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Junseok Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Translational Research and Molecular Imaging, The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Toll-Like Receptor 5, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health & Welfare, Republic of Korea.
Abstract (Originalsprache)
Immune checkpoint inhibitors have revolutionized anti-tumor therapy, notably improving treatment responses in various tumors. However, many patients remain non-responsive and do not experience benefits. Given that Toll-like receptors (TLRs) can counteract tumor immune tolerance by stimulating both innate and adaptive immune responses, TLR agonists are being explored as potential immune adjuvants for cancer treatment. In this study, we assessed the potential of enhancing the efficacy of immune checkpoint inhibitors by activating innate immunity with a TLR5 agonist. In a mouse tumor model, combination therapy with TLR5 agonist and anti-PD-1 significantly inhibited tumor growth. The TLR5 agonist shifted the balance from M2-like to M1-like macrophages and upregulated the expression of co-stimulatory molecules in macrophages. Furthermore, TLR5 agonist promoted the activation and tumor infiltration of CD8 + T cells. As a result, the TLR5 agonist augmented the anti-tumor efficacy of anti-PD-1, suggesting its potential in modulating the tumor microenvironment to enhance the anti-tumor response. Our findings point toward the possibility of optimizing immune checkpoint inhibitor therapy using TLR5 agonists.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Translational Research and Molecular Imaging, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Institute for Translational Research and Molecular Imaging, The Catholic University of Korea, Seoul, Republic of Korea. chosg@catholic.ac.kr.
- Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. chosg@catholic.ac.kr.
- Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. chosg@catholic.ac.kr.
Förderung
- Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Lee, J., Im, K. I., Gil, S., Na, H., Min, G. J., Kim, N., & Cho, S. G. (2024). TLR5 agonist in combination with anti-PD-1 treatment enhances anti-tumor effect through M1/M2 macrophage polarization shift and CD8+ T cell priming. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03679-5
Vancouver
Lee J, Im KI, Gil S, Na H, Min GJ, Kim N, et al. TLR5 agonist in combination with anti-PD-1 treatment enhances anti-tumor effect through M1/M2 macrophage polarization shift and CD8+ T cell priming. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03679-5
BibTeX
@article{Lee2024,
author = {Lee, Junseok and Im, Keon-Il and Gil, Sojin and Na, Hyemin and Min, Gi-June and Kim, Nayoun and Cho, Seok-Goo},
title = {TLR5 agonist in combination with anti-PD-1 treatment enhances anti-tumor effect through M1/M2 macrophage polarization shift and CD8+ T cell priming},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03679-5}
}
EUVIMED